GMP | Jotup

Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

Retrieved on:

Tuesday, March 26, 2024

TOKYO, March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).

Key Points:

TOKYO, March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium.
The product line-up of StemFit™ is ideal for regenerative medicine, drug discovery and disease modeling.
Additionally, it also enhances further manufacturing of cellular medicines, ensuring superior performance and reliability in iPSC culture.
The Group's expertise in GMP API production contributes to the superior performance of the StemFit™ medium, ensuring it meets the highest industry standards.

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on:

Monday, March 25, 2024

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points:

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
"Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on:

Monday, March 25, 2024

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points:

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
"Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

MediPharm Labs Provides Update on German Cannabis Legalization

Retrieved on:

Monday, March 25, 2024

Federation, MPL, Patient, Pharmacy, GMP, Cannabis, TSX, API, Physician, Legislation, Drug

The new legislation that takes effect April 1, 2024, also removes medical cannabis from the German narcotic list, removing access barriers for patients.

Key Points:

The new legislation that takes effect April 1, 2024, also removes medical cannabis from the German narcotic list, removing access barriers for patients.
TORONTO, March 25, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on German cannabis legalization.
The removal of cannabis from narcotic status will open the opportunity for more physicians, pharmacies, and patients to participate in the current German medical cannabis market.
Located in Potsdam, the business holds a suite of German GMP medical cannabis licenses to import, wholesale and distribute GMP cannabis products.

Unravel Announces Initiation of RVL001 Clinical Trial Material Manufacturing to Support Upcoming US and International Clinical Trials in Rett Syndrome

Retrieved on:

Tuesday, March 19, 2024

Incidence, Partnership, QCL, Female, GMP, Rett syndrome, Clinical trial, Therapy, FDA, Pharmaceutical industry

BOSTON, March 19, 2024 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company established to advance drugs for complex diseases, today announced a manufacturing and development partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture RVL001 clinical trial material for use in upcoming Rett syndrome clinical trials in the US and Colombia. The collaboration with QCL is part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by Unravel.

Key Points:

Manufacturing of GMP material for clinical trials represents key step towards initiation of clinical studies.
The collaboration with QCL is part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by Unravel.
RVL001 will be tested in the US and in Colombia in proof-of-concept clinical trials as a key path to effective Rett syndrome treatment.
"The initiation of manufacturing clinical trial material is a key remaining step to initiating clinical testing in our global Rett syndrome RVL001 trials."

Curaleaf to Acquire Northern Green Canada to Bolster European Flower Supply

Retrieved on:

Tuesday, March 19, 2024

Certification, Establishment, Acquisition, NGC, GMP, Cannabis, TSX, GACP, THC, Drug

NEW YORK, March 19, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced it has signed a deal to acquire Northern Green Canada ("NGC"), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Key Points:

NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.
By integrating NGC, Curaleaf can significantly increase its European margins while extending its global footprint across three continents: North America, Europe, and Australasia (Australia/New Zealand).
It allows Curaleaf to safeguard our position in Europe, enhancing our supply chain while increasing our margins.
Lisa McCormack, President and CEO of Northern Green Canada, said, "The NGC team is excited to become a part of the Curaleaf family.

Curaleaf to Acquire Northern Green Canada to Bolster European Flower Supply

Retrieved on:

Tuesday, March 19, 2024

Certification, Establishment, Acquisition, NGC, GMP, Cannabis, TSX, GACP, THC, Drug

NEW YORK, March 19, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced it has signed a deal to acquire Northern Green Canada ("NGC"), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Key Points:

NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.
By integrating NGC, Curaleaf can significantly increase its European margins while extending its global footprint across three continents: North America, Europe, and Australasia (Australia/New Zealand).
It allows Curaleaf to safeguard our position in Europe, enhancing our supply chain while increasing our margins.
Lisa McCormack, President and CEO of Northern Green Canada, said, "The NGC team is excited to become a part of the Curaleaf family.

Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

Retrieved on:

Thursday, March 14, 2024

Patient, Public, OUD, Research, Columbia University, Opioid use disorder, IND, GMP, Report, Ibogaine, Toxicology, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental health disorders, today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders. As summarized in a recent New York Times article (Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction), ibogaine, a plant-derived psychoactive compound, has accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders. However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.

Key Points:

However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.
This grant provides non-dilutive funding to support IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials in healthy volunteers and opioid use disorder (OUD) patients for GM-3009.
The planned clinical work will seek to confirm that GM-3009 eliminates the cardiovascular risks associated with ibogaine and demonstrate proof-of-concept efficacy in attenuating symptoms associated with OUD.
As Gilgamesh moves forward with its clinical trials, the company is poised to lead a new era in addiction treatment, marked by safer, more effective, and scientifically validated therapies.

List Biotherapeutics and Sacco System Announce Lead Share Agreement

Retrieved on:

Thursday, March 14, 2024

Probiotic, CGMP, Protein, GMP, Catalog, Therapy, Fermentation, Fine chemical

INDIANAPOLIS and YEERONGPILLY, Australia, March 14, 2024 /PRNewswire/ -- List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce and mutually recommend each other's microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party's capability or capacity.

Key Points:

INDIANAPOLIS and YEERONGPILLY, Australia, March 14, 2024 /PRNewswire/ -- List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce and mutually recommend each other's microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party's capability or capacity.
Sacco specializes in the development and production of probiotics, postbiotics and live bacterial therapeutics for the agri-food, food supplements and pharmaceutical industry.
List Bio and its sister company, List Labs, specialize in the development and production of innovative bacterial based therapeutic products, including GMP Manufacturing of live biotherapeutic products (LBPs), and other types of microbiome-based therapeutics.
Sacco Managing Director John Goebel said, "Sacco looks forward to offering our large-scale fermentation capabilities to any List Bio or List Labs biotherapeutics clients who wish to manufacture probiotics and LBPs in large volume.

Allumiqs and Prolytix form strategic partnership to accelerate drug discovery and development

Retrieved on:

Wednesday, March 13, 2024

Partnership, GMP, 2005 in television, Research, Investment, News, LC-MS/MS, NS, Fine chemical

HALIFAX, NS and ESSEX JUNCTION, Vt., March 13, 2024 /PRNewswire/ -- Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines. Together the partners empower customers with bioanalytical solutions to advance drug candidates from the early R&D phases through to lot release.

Key Points:

HALIFAX, NS and ESSEX JUNCTION, Vt., March 13, 2024 /PRNewswire/ -- Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines.
This strategic collaboration comes after several successful joint customer engagements, leveraging Allumiqs' expertise in multiomics and LC-MS/MS solutions and Prolytix's complementary large- molecule drug product lifecycle management.
Collectively the partners offer cohesive solutions that optimize efficiency and accelerate advancements in the drug development pipeline.
Now in partnership with Prolytix we can take all of our customers further in the drug development process with connected solutions from early R&D to lot release.